SGLT2 inhibitor dapagliflozin enhances skeletal muscle fatty acid uptake in subjects with type 2 diabetes: a positron emission tomography study

被引：0
|
作者：
Latva-Rasku, A. [1 ]
Tuisku, J. [1 ]
Bhowmik, A. [1 ]
Keskinen, H. [1 ]
Rebelos, E. [1 ]
Laurila, S. [1 ]
Koffert, J. [1 ]
Nummenmaa, L. [1 ]
Heurling, K. [2 ]
Oscarsson, J. [3 ]
Turku, P. Nuutila [1 ]
机构：
[1] Univ Turku, Turku PET Ctr, Turku, Finland
[2] Antaros Med, Molndal, Sweden
[3] AstraZeneca AB, Molndal, Sweden
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
133
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [31] Bexagliflozin (Brenzavvy) - A Fifth SGLT2 Inhibitor for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1683): : 130 - 132
  • [32] Effects of Dapagliflozin, an SGLT2 Inhibitor, on Hepatic Steatosis and Fibrosis Evaluated by Transient Elastography in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
    Aso, Yoshimasa
    Jojima, Teruo
    Iijima, Toshie
    Usui, Isao
    DIABETES, 2019, 68
  • [33] Is an SGLT2 inhibitor right for your patient with type 2 diabetes?
    Lisenby, Katelin M.
    Meyer, Allison
    Slater, Nicole A.
    JOURNAL OF FAMILY PRACTICE, 2016, 65 (09): : 587 - 593
  • [34] Insulin Independence With SGLT2 Inhibitor Use in Type 2 Diabetes
    Jack, Gwendolyne Anyanate
    Kashyap, Sangeeta R.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (10): : E1153 - E1154
  • [35] Ketoacidosis in Type 2 Diabetes with and without SGLT2 Inhibitor Therapy
    Koerbel, Theresa
    Zitterl, A.
    Jagoutz, T.
    Peric, S.
    Stulnig, T. M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S765 - S765
  • [36] Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
    Kaushal, Shaveta
    Singh, Harmanjit
    Thangaraju, Pugazhenthan
    Singh, Jasbir
    NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2014, 6 (03) : 107 - 113
  • [37] Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
    Nigro, Stefanie C.
    Riche, Daniel M.
    Pheng, Michelle
    Baker, William L.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (10) : 1301 - 1311
  • [38] Case History: Forxiga™ (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes
    Washburn, William N.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 363 - 382
  • [39] A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
    Christian Ott
    Agnes Jumar
    Kristina Striepe
    Stefanie Friedrich
    Marina V. Karg
    Peter Bramlage
    Roland E. Schmieder
    Cardiovascular Diabetology, 16
  • [40] A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
    Ott, Christian
    Jumar, Agnes
    Striepe, Kristina
    Friedrich, Stefanie
    Karg, Marina V.
    Bramlage, Peter
    Schmieder, Roland E.
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
12345